BN vs MFG

The deterministic health scores present a mixed picture: the Piotroski F-Score of 4/9 indicates borderline stable financial health, while the absence of an Altman Z-Score prevents a clear distress risk assessment. Despite a high forward P/E of 8.04 suggesting reasonable future earnings expectations, the trailing P/E of 131.03 reflects significant volatility or one-time impacts. Earnings growth is highly volatile with a YoY surge of 719.20%, but recent quarters show deteriorating performance, including a -91.3% YoY EPS drop and consistent earnings misses. The stock trades well above the Graham Number of $12.39 and intrinsic value of $10.62, implying substantial premium pricing based on growth and market sentiment rather than defensive or fundamental value.

MFG presents a stark dichotomy between poor operational health (Piotroski F-Score: 2/9) and highly attractive valuation metrics. The stock is currently trading near its Graham Number ($8.22) and significantly below its growth-based intrinsic value ($15.64). While the company demonstrates strong earnings growth (16.4% YoY) and a compelling forward P/E of 6.06, the low F-Score suggests deteriorating fundamental trends that offset the valuation appeal. Consequently, the stock is a high-value play burdened by significant internal health warnings.